Navigation Links
Still River Systems Announces Operation of the World's Highest Magnetic Field Cyclotron
Date:5/21/2008

LITTLETON, Mass., May 21 /PRNewswire/ -- Still River Systems announces the successful development and operation of the world's highest magnetic field cyclotron as part of the development of its Monarch250(TM) proton therapy system. This cyclotron is operating at 10 Tesla and conclusively demonstrates that cyclotrons at this high field strength can be designed and optimized for proton radiation therapy. By increasing the operating magnetic field, Still River Systems is developing a cyclotron that weighs less than 20 tons, a 90% reduction over the current generation of proton therapy cyclotrons. "We are excited to report this technical breakthrough," says Kenneth Gall, Ph.D., Chief Technology Officer and Founder of Still River Systems. "While magnets of this strength are already in use in medical applications, the challenge has been to operate a cyclotron at this very large magnetic field."

Conventional proton radiation therapy cyclotrons are based on non-superconducting technology, and operate at low magnetic fields. In 2004, Still River Systems partnered with the Massachusetts Institute of Technology (MIT) to develop this next generation of proton therapy cyclotron using high magnetic field technology currently used in research and Magnetic Resonance Imaging (MRI) applications. "Our goal is to make proton radiation therapy treatment available to hospitals and cancer centers worldwide. This was only possible through a significant reduction in the cost and size of the proton therapy equipment and facility which can be achieved by using high-magnetic field technology," says Marc Buntaine, Chief Executive Officer of Still River Systems.

About The Monarch250

The Monarch250 is the next generation of proton radiation therapy systems. Based on Still River Systems high-magnetic field cyclotron, combined with proven proton therapy technology, the Monarch250 is being integrated with well established clinical systems such as patient radiographic and cone beam CT imaging, high-precision robotic treatment couch, oncology information systems and treatment planning systems. The compact, precise and affordable design of the Monarch250 proton therapy system provides the most versatile proton treatment capabilities, enhancing existing department capacity. For large multiple room proton centers, the Monarch250 unique configuration of one-cyclotron for each room will provide the most reliable, efficient and economical approach to proton therapy. The Monarch250 has not been cleared for commercial distribution/clinical use by the US Food and Drug Administration and is currently in development.

About Still River Systems

Still River Systems, based in Littleton, Massachusetts, is dedicated to providing physicians and their patients access to high quality, cost-effective proton therapy solutions, and to help establish this superior treatment modality as a standard of care for patients worldwide. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit their website @ http://www.StillRiverSystems.com.


'/>"/>
SOURCE Still River Systems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
2. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
3. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
4. Federal nanotech risk research plan still comes up short
5. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
6. Dr. Arie S. Belldegrun, MD, FACS Joins Two River Group Holdings as Chairman and Partner
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
9. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. NxStage Medical Provides Update on Medisystems Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Dutch philosopher Koert van Mensvoort - founder of the Next Nature ... Eindhoven - has written a ,Letter to Humanity, in support of ... becoming a slave and victim to its own technology, but to employ technology ... ... Mensvoort – founder of the Next Nature Network and Fellow of ‘Next Nature’ ...
(Date:4/20/2017)... , April 20, 2017 For ... focuses on novel drug development and clinical research aimed at ... Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite ... ZIOP ). You can access our complimentary research reports ... ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments ... which is part of the Protein and Cell Analysis Education Webinar Series , ... this technology fits in current and future applications. , Many flow cytometers have ...
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... ... Halo Labs . The move comes after the company changed focus to ... market, our new brand and our new technology,” says CEO Robert Hart. Founders ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):